UCSF researchers reported a dual‑vector system that achieves programmable, site‑specific integration of large DNA payloads into human T cells without ex vivo manufacturing. The team, led by Justin Eyquem and published in GEN coverage of the work, demonstrated durable, locus‑specific CAR expression and tumor control in humanized mice. Separately, Azalea Therapeutics (a Jennifer Doudna lab spinout) published Nature data showing in vivo CAR‑T generation that cleared solid and blood tumors in mice. STAT coverage highlighted the platform’s cell and locus specificity, which the authors argue reduces off‑target editing risks compared with prior in vivo approaches. Both reports directly address manufacturing, cost and access barriers by eliminating centralized cell processing and suggest a viable path to scalable, off‑the‑shelf‑style CAR therapies made inside the patient.